Topical Application of Ursolic Acid Cream Ameliorates Imiquimod-induced Plaque Psoriasis in BALB/c Mice

Jump To References Section

Authors

  • Precious Derera
     Department of Pharmacy, Harare Institute of Technology, Harare - BE 277 ,ZW
  • M. Sumithra
     Department of Pharmacology, SRM College of Pharmacy, SRM Institute of Science and Technology, Kattankulathur - 603203, Tamil Nadu ,IN
  • V. Chitra
     Department of Pharmacology, SRM College of Pharmacy, SRM Institute of Science and Technology, Kattankulathur - 603203, Tamil Nadu ,IN
  • R. Mrinalini
     Department of Pharmacology, SRM College of Pharmacy, SRM Institute of Science and Technology, Kattankulathur - 603203, Tamil Nadu ,IN
  • Rukaiah Fatma Begum
     Department of Pharmacology, SRM College of Pharmacy, SRM Institute of Science and Technology, Kattankulathur - 603203, Tamil Nadu ,IN

DOI:

https://doi.org/10.18311/jnr/2023/29734

Keywords:

Imiquimod, Inflammation, Interleukin-17, Psoriasis, Ursolic Acid

Abstract

The valued studies of alternative psoriasis treatment options are in a much higher need among the Scientific Community. This study aimed to evaluate the anti-psoriatic activity of ursolic acid cream in imiquimod-induced psoriasis in BALB/c mice. The creams containing ursolic acid, a pentacyclic triterpenoid at percentages of 0.1 and 0.2% were formulated. The pH, spreadability, physical characteristics and acute dermal irritation of the cream were assessed. Animals were grouped into five each having 6 animals. Clobetasol, a topical corticosteroid, was used as the standard. One group was used as control and four groups were treated with the formulated imiquimod cream while receiving treatment. Parameters such as skin inflammation severity, ear thickness, plasma level of interleukins (IL)-17, histology of the back of the skin and spleen weight were evaluated. Erythema and scales were scored on a daily basis with the 0.1 and 0.2% ursolic acid cream significantly ameliorating psoriatic-like symptoms in a manner comparable to clobetasol. Imiquimod-induced epidermal hyperplasia and inflammation were inhibited by topical application of ursolic acid as shown by the results of histopathology. Spleens of the positive control group were larger in comparison with the rest of the groups. BALB/c mice treated with ursolic acid creams exhibited a decrease in the plasma levels of cytokines IL-17 when compared to the positive control group. The result of this study provided an insight that topical application of ursolic acid can be a potential treatment for psoriasis.

Downloads

Download data is not yet available.

Metrics

Metrics Loading ...

Downloads

Published

2023-03-23

How to Cite

Derera, P., Sumithra, M., Chitra, V., Mrinalini, R., & Begum, R. F. (2023). Topical Application of Ursolic Acid Cream Ameliorates Imiquimod-induced Plaque Psoriasis in BALB/c Mice. Journal of Natural Remedies, 23(1), 79–87. https://doi.org/10.18311/jnr/2023/29734

Issue

Volume 23, Issue 1, January 2023

Section

Research Articles

License

Copyright (c) 2023 Precious Derera, Sumithra M, Chitra V, Mrinalini R

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

Crossref
Scopus
Google Scholar
Europe PMC
Received 2022-03-07
Accepted 2023-03-23
Published 2023-03-23

 

References

Thomas PS, Pathology VK. Philadelphia, Pa. Blakiston's son; 2007.

Dipiro JT, Talbert RL, Yee GC, Matzke GR, Wells BG, Posey LM. Pharmacotherapy: A Pathophysiologic Approach, ed. Connecticut: Appleton and Lange. 2014; 4:141-2.

Walker R. Clinical pharmacy and therapeutics E-Book. Elsevier Health Sciences; 2011; Oct 24.

Hammer GD, McPhee SJ, Education MH, editors. Pathophysiology of disease: an introduction to clinical medicine. McGraw-Hill Education Medical; 2014.

Schon MP, Boehncke WH, Brocker EB. Psoriasis: clinical manifestations, pathogenesis and therapeutic perspectives. Discov Med. 2009; 5(27):253-8.

Naldi L. Psoriasis and smoking: links and risks. Psoriasis (Auckland, NZ). 2016; 6:65. https://doi.org/10.2147/PTT. S85189

Casciano F, Pigatto PD, Secchiero P, Gambari R, Reali E. T cell hierarchy in the pathogenesis of psoriasis and associated cardiovascular comorbidities. Front Immunol. 2018; 9:1390. https://doi.org/10.3389/fimmu.2018.01390

8. Lowes MA, Bowcock AM, Krueger JG. Pathogenesis and therapy of psoriasis. Nature. 2007; 445(7130):866-73. https://doi.org/10.1038/nature05663

Vena GA, Vestita M, Cassano N. Psoriasis and cardiovascular disease. Dermatol. Ther. 2010; 23(2):144-51. https://doi. org/10.1111/j.1529-8019.2010.01308.x

Fernandez-Armenteros JM, Gomez-Arbones X, Buti-Soler M, Betriu-Bars A, Sanmartin-Novell V, Ortega-Bravo M, Martínez-Alonso M, Gari E, Portero-Otín M, SantamariaBabi L, Casanova-Seuma JM. Psoriasis, metabolic syndrome and cardiovascular risk factors. A population-based study. J Eur Acad Dermatol Venereol. 2019; 33(1):128-35. https:// doi.org/10.1111/jdv.15159

Kim WB, Jerome D, Yeung J. Diagnosis and management of psoriasis. CFP. 2017; 63(4):278-85.

Afifi T, de Gannes G, Huang C, Zhou Y. Topical therapies for psoriasis: Evidence-based review. CFP. 2005; 51(4):519-25.

Kang SY, Yoon SY, Roh DH, Jeon MJ, Seo HS, Uh DK, Kwon YB, Kim HW, Han HJ, Lee HJ, Lee JH. The antiarthritic effect of ursolic acid on zymosan-induced acute inflammation and adjuvant-induced chronic arthritis models. J Pharm Pharmacol. 2008; 60(10):1347-54. https:// doi.org/10.1211/jpp.60.10.0011

Murphy BT, MacKinnon SL, Yan X, Hammond GB, Vaisberg AJ, Neto CC. Identification of triterpene hydroxycinnamates with in vitro antitumor activity from whole cranberry fruit (Vaccinium macrocarpon). J Agric Food Chem. 2003; 51(12):3541-5. https://doi.org/10.1021/jf034114g

Wozniak L, Skapska S, Marszalek K. Ursolic acid-a pentacyclic triterpenoid with a wide spectrum of pharmacological activities. Molecules. 2015; 20(11):20614- 41. https://doi.org/10.3390/molecules201119721

Ikeda Y, Murakami A, Ohigashi H. Ursolic acid: An antiand pro-inflammatory triterpenoid. Mol Nutr Food Res. 2008; 52(1):26-42. https://doi.org/10.1002/mnfr.200700389

Liu W, Tan X, Shu L, Sun H, Song J, Jin P, Yu S, Sun M, Jia X. Ursolic acid inhibits cigarette smoke extract-induced human bronchial epithelial cell injury and prevents development of lung cancer. Molecules. 2012; 17(8):9104- 15. https://doi.org/10.3390/molecules17089104

Sultana N. Clinically useful anticancer, antitumor, and antiwrinkle agent, ursolic acid and related derivatives as medicinally important natural product. J Enzyme Inhib Med Chem. 2011; 26(5):616-42. https://doi.org/10.3109/14 756366.2010.546793

Do Nascimento PG, Lemos TL, Bizerra A, Arriaga A, Ferreira DA, Santiago GM, Braz-Filho R, Costa JG. Antibacterial and antioxidant activities of ursolic acid and derivatives. Molecules. 2014; 19(1):1317-27. https://doi. org/10.3390/molecules19011317

Jin YR, Jin JL, Li CH, Piao XX, Jin NG. Ursolic acid enhances mouse liver regeneration after partial hepatectomy. Pharm Biol. 2012; 50(4):523-8. https://doi.org/10.3109/13880209.2 011.611143

Nema RK, Rathore KS, Dubey BK. Textbook of cosmetics. CBS Publishers and Distributors; 2009.

Dhyani A, Chander V, Singh N. Formulation and evaluation of multipurpose herbal cream. J Drug Deliv Ther. 2019; 9(2):341-3. https://doi.org/10.22270/jddt.v9i2.2540

OECD Guideline: OECD 404.

Sun J, Zhao Y, Hu J. Curcumin inhibits imiquimod-induced psoriasis-like inflammation by inhibiting IL-1beta and IL-6 production in mice. PloS one. 2013; 8(6):e67078. https:// doi.org/10.1371/journal.pone.0067078

Dou R, Liu Z, Yuan X, Xiangfei D, Bai R, Bi Z, Yang P, Yang Y, Dong Y, Su W, Li D. PAMs ameliorates the imiquimodinduced psoriasis-like skin disease in mice by inhibition of translocation of NF-κB and production of inflammatory cytokines. PLoS One. 2017; 12(5):e0176823. https://doi. org/10.1371/journal.pone.0176823

Zhao J, Di T, Wang Y, Wang Y, Liu X, Liang D, Li P. Paeoniflorin inhibits imiquimod-induced psoriasis in mice by regulating Th17 cell response and cytokine secretion. Eur J Pharmacol. 2016; 772:131-43. https://doi.org/10.1016/j. ejphar.2015.12.040

Chen YH, Wu CS, Chao YH, Lin CC, Tsai HY, Li YR, Chen YZ, Tsai WH, Chen YK. Lactobacillus pentosus GMNL-77 inhibits skin lesions in imiquimod-induced psoriasis-like mice. J Food Drug Anal. 2017; 25(3):559-66. https://doi. org/10.1016/j.jfda.2016.06.003

Kuchekar S, Bhise K. Formulation and development of antipsoriatic herbal gelcream. J Sci Ind Res. 2012; 71(4):279- 284.

Gilliet M, Conrad C, Geiges M, Cozzio A, Thürlimann W, Burg G, Nestle FO, Dummer R. Psoriasis triggered by toll-like receptor 7 agonist imiquimod in the presence of dermal plasmacytoid dendritic cell precursors. Arch Dermatol. 2004; 140(12):1490-5. https://doi.org/10.1001/ archderm.140.12.1490

Van Der Fits L, Mourits S, Voerman JS, Kant M, Boon L, Laman JD, Cornelissen F, Mus AM, Florencia E, Prens EP, Lubberts E. Imiquimod-induced psoriasis-like skin inflammation in mice is mediated via the IL-23/IL-17 axis. J Immunol. 2009; 182(9):5836-45. https://doi.org/10.4049/ jimmunol.0802999

Sonja Moos, Alma N Mohebiany, Ari Waisman Florian C. Kurschus. Imiquimod-Induced Psoriasis in Mice Depends on the IL-17 Signaling of Keratinocytes. J Invest Dermatol. 2019; 139(5):1110-1117. https://doi.org/10.1016/j. jid.2019.01.006

Thaci D, Humeniuk J, Frambach Y, Bissonnette R, Goodman JJ, Shevade S, Gong Y, Papavassilis C, STATURE Study Group. Secukinumab in psoriasis: randomized, controlled phase 3 trial results assessing the potential to improve treatment response in partial responders (STATURE). British Journal of Dermatology. 2015; 173(3):777-87. https://doi.org/10.1111/bjd.13814